Mereo Biopharma Group Plc Overview
Valuation check: MREO's P/E ratio is -1.54, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-1.54
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Mereo Biopharma Group Plc (MREO) currently reports a P/E ratio of -1.54. That is below the Healthcare sector average of 24.78. Use the charts on this page to explore Mereo Biopharma Group Plc's P/E ratio history and peer comparisons.
Mereo Biopharma Group Plc's P/E ratio of -1.54 is lower than the Healthcare sector average of 24.78. That is roughly 106.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Mereo Biopharma Group Plc's market price to a fundamental measure such as earnings, sales, or book value. At -1.54, MREO can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -1.54, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for Mereo Biopharma Group Plc, and consider following MREO for alerts when major investors trade the stock.
Mereo Biopharma Group Plc is classified in the Healthcare sector. On P/E ratio, it currently shows -1.54 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MREO with unrelated industries.
